Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYAD-101 with FOLFOX and Pembrolizumab in Metastatic Colorectal Cancer
NCT04991948Phase 1Recruiting
- Sponsor
- Celyad Oncology
- Start
- Nov 2021
- Primary completion
- Aug 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of CYAD-101 in metastatic colorectal cancer (mCRC), sponsored by Celyad Oncology. Primary endpoints: Occurrence of Dose Limiting Toxicities and Objective Response Rate at Day 94. Started Nov 2021; status: recruiting.
02
Drugs
CYAD-101
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04991948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991948.